Cellular immunodeficiency in Paget's disease of bone: changes induced by treatment with elcatonin.
We have found a cellular immune defect (low CD4 T lymphocyte count, high CD8 T lymphocyte count and a low CD4/CD8 ratio) in 39 PDB patients. This finding is not correlated with the bone metabolic activity of the disease. There was an improvement in the cellular immune defect in fifteen patients after treatment with elcatonin. These changes could be related to the improvement in the metabolic derangement or else could be the consequence of an effect on altered immunity.
Rapado
A
A
Service of Internal Medicine (Unidad Metabólica), Fundación Jiménez Diaz, Madrid, Spain.
Yague
M
M
Diaz Curiel
M
M
Ortiz
F
F
Palomino
P
P
de la Piedra
C
C
Torres
R
R
Peramo
B
B
Lopez Gavilanes
E
E
D000368:Aged; D016516:CD4-CD8 Ratio; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D002116:Calcitonin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D010001:Osteitis Deformans / Q000188:drug therapy / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology*
D002116:Calcitonin; C012755:elcatonin